^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Squamous Cell Skin Cancer

    Related cancers:
    7d
    ETCABIO: Evaluation of Skin Tests in Biotherapy Allergies (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, University Hospital, Angers | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    Integrated transcriptomics identifies HIF1A and GSTP1 as biomarkers for cutaneous squamous cell carcinoma. (PubMed, Transl Cancer Res)
    Drug prediction and docking identified camptothecin, hydroquinone, and resveratrol with favorable binding (e.g., HIF1A-camptothecin -8.7 kcal/mol; GSTP1-camptothecin -8.6 kcal/mol)...Keratinocyte pseudotime revealed progression from normal to metastatic states with concordant keratinocyte‑related gene programs. HIF1A and GSTP1 are promising diagnostic biomarkers for cSCC, linked to altered immune landscapes, enhanced intercellular signaling, and potential druggable interactions.
    Journal
    |
    CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • GSTP1 (Glutathione S-transferase pi 1)
    8d
    Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients (clinicaltrials.gov)
    P=N/A, N=28, Recruiting, Alpha Tau Medical LTD. | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial primary completion date
    9d
    Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=86, Active, not recruiting, Alpha Tau Medical LTD. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    12d
    Single-Cell Transcriptomic Mapping of PD-L1/TLR4 Remodeling Informs Topical Immunoprevention Timing in Skin Carcinogenesis. (PubMed, bioRxiv)
    Dendritic cells shifted from early inflammatory antigen-presenting programs toward late PD-L1 / IFN -regulatory states; macrophages showed monotonically increasing TLR4 -associated myeloid activation; and T cells defined a "hot but exhausted" microenvironment in established cSCC. These findings identify SD and AK as biologically active stages for topical immunoprevention and provide a cellular roadmap for PD-L1 / PD-1 and TLR4 blockade strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD27 (CD27 Molecule) • TLR4 (Toll Like Receptor 4) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    PD-L1 expression
    12d
    p53 overexpression counteracts the pro-survival effect of Bcl-2 by restoring MAMs function in cutaneous squamous cell carcinoma. (PubMed, Cell Div)
    Our findings demonstrate that Bcl-2 promotes cSCC progression by modulating MAMs structure and function to inhibit p53-mediated mitochondrial apoptosis. The study identifies the novel Bcl-2-MAMs-p53 signaling axis that plays a pivotal role in determining cSCC cell fate, highlighting a promising target for therapeutic intervention.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    13d
    Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors. (PubMed, Immunity)
    Neoantigens with features shared with validated immunogenic neoantigens were decreased in clonal relative to subclonal cancer cell populations in high-immune-infiltrate tumors from immunocompetent patients. Thus, the immune system restricts cancer cells expressing immunogenic antigens from clonal populations in primary, treatment-naive human tumors.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    14d
    CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling. (PubMed, Cell Death Dis)
    Collectively, our findings identify CD70 as a stress-inducible signaling hub that links DNA damage, inflammation, and tumor-stromal communication in skin carcinogenesis. Targeting CD70 may disrupt this feed-forward inflammatory circuit and provide a therapeutic strategy for UV-driven and inflammation-associated cSCC.
    Journal
    |
    IL6 (Interleukin 6) • CD70 (CD70 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • E2F1 (E2F transcription factor 1)
    15d
    Expression of epigenetic marker EZH2 in squamous cell carcinoma of skin. (PubMed, J Pak Med Assoc)
    Enhancer of zeste homologue 2 overexpression was noted in cutaneous squamous cell carcinoma cases, indicating that enhancer of zeste homologue 2 had a potential role in cutaneous squamous cell carcinoma tumourigenesis.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    16d
    POTENTIATE: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications (clinicaltrials.gov)
    P1, N=85, Terminated, Boundless Bio, Inc. | Trial completion date: Mar 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Mar 2026; Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    erlotinib • Lytgobi (futibatinib)
    21d
    Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=39, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Feb 2027 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Tumor mutational burden
    |
    camonsertib (RP-3500)